2024-2025 RSV Program
Beyfortus® (Nirsevimab) Guidance for Health Care Providers document was updated (October) and the section below was updated with this new link
Please see below for more information on the 2024-2025 Respiratory Syncytial Virus (RSV) program.
The program was updated for 2024-2025.
Eligibility
Eligibility in Ontario for high risk older adults was recently expanded to include anyone who is 60 YEARS AND OLDER AND a member of any of the following groups:
- Living in long-term care homes, including Elder Care Lodges, and retirement homes
- A hospital alternate level of care (ALC) patient
- A dialysis patient (hemodialysis or peritoneal dialysis)
- A transplant recipient (solid organ or hematopoietic stem cell)
- Experiencing homelessness
- Indigenous; First Nations, Inuit, or Métis
Ordering Vaccine
- Thunder Bay Providers - Use the Thunder Bay Providers RSV Form (PDF - Updated September 2024)
- District Providers - Use the District Providers RSV Form (PDF - Updated September 2024)
Provider Resources
Public/Patient Resources
Eligibility
Monoclonal antibody product Beyfortus® will be publicly funded and available this fall (anticipate availability of vaccine starting in October) to infants and children who are residents of Ontario and meet any of the following criteria:
- born in 2024 prior to the RSV season (the National Advisory Committee on Immunization (NACI) (French) specifically recommends that infants 8 months of age or less receive the product)
- born during the 2024–25 RSV season
- children up to 24 months of age who remain vulnerable from severe RSV disease through their second RSV season, following discussion with a health care provider; see a list of health conditions by visiting Ontario's Respiratory Syncytial Virus (RSV) prevention programs web page (French).
Guidance
- Beyfortus® (Nirsevimab) (French) - Updated October 2024
- AbrysvoTM (French) - Updated October 2024
Ordering Vaccine
- Thunder Bay Providers - Use the Thunder Bay Providers RSV Form (PDF - Updated September 2024)
- District Providers - Use the District Providers RSV Form (PDF - Updated September 2024)
Reporting Vaccines
Please report all vaccines administered to children 0-18 years to ensure their records are up to date by using the forms listed below.
Thunder Bay Providers - Use the Reporting Form (PDF) (Updated September 2024)
- Email to vaccines@tbdhu.com or fax to 807-625-4828.
- NOTE: A SUBMIT button is available at the bottom right of the form which will allow the completed form to be automatically attached to an email addressed to vaccines@tbdhu.com.
District Providers - Select the Reporting Form (PDF) for the branch office nearest to your practice; Marathon/Manitouwadge, Terrace Bay/Schreiber, Red Rock/Nipigon OR Greenstone (Updated September 2024)
- Submit the form using the email address or fax number listed on the form.
Public Resources
- RSV Immunity fact sheet (French) - Information for individuals on immunity, monoclonal antibodies and vaccination for infants and high-risk children
- Abrysvo in pregnancy fact sheet (French) - Information for individuals on the RSV vaccine Abrysvo for pregnant individuals
- Beyfortus fact sheet (French) - Information for individuals on the RSV monoclonal antibody Beyfortus for infants
Recommended Approach
Although giving the monoclonal antibody to an infant is the recommended approach over vaccination in pregnancy to protect infants, an RSV vaccine, Abrysvo®, may be recommended for pregnant people who do not wish to or are not able to protect their infant using the monoclonal antibody.
The monoclonal antibody approach is based on
- efficacy (how well it works)
- duration of protection
- safety profile of the monoclonal antibody, Beyfortus®; preferred product in alignment with NACI (French)
- recommendations from NACI
Receiving both Abrysvo® and Beyfortus® is not expected to provide additional benefit.
Eligibility
The RSV vaccine will be available to residents of Ontario who are 32 to 36 weeks pregnant and who will deliver near the start of or during the RSV season with the goal of helping the patient's immune system create antibodies to protect the baby from RSV from birth until 6 months old.
Guidance
- Beyfortus® (Nirsevimab) (French) - Updated October 2024
- AbrysvoTM (French) - Updated October 2024
Ordering Vaccine
- Thunder Bay Providers - Use the Thunder Bay Providers RSV Form (PDF - Updated September 2024)
- District Providers - Use the District Providers RSV Form (PDF - Updated September 2024)
Public Resources
- RSV Immunity fact sheet (French) - Information for individuals on immunity, monoclonal antibodies and vaccination for infants and high-risk children
- Abrysvo in pregnancy fact sheet (French) - Information for individuals on the RSV vaccine Abrysvo for pregnant individuals
- Beyfortus fact sheet (French) - Information for individuals on the RSV monoclonal antibody Beyfortus for infants